Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe
dose level of this drug in patients with advanced solid tumor cancers.